Klobazāms

Clobazam is a long-acting benzodiazepine derivative belonging to the unique 1,5-benzodiazepine subclass, distinguishing it from the more common 1,4-benzodiazepines. First synthesized in 1966 and patented in 1968, it was initially marketed as an anxiolytic before gaining approval for epilepsy treatment in 1984. Clobazam demonstrates a more favorable side-effect profile than older benzodiazepines, with notably less sedation and memory impairment, and shows a distinct addictive potential compared to its 1,4-benzodiazepine counterparts.

Also known as: Onfi, Frisium, Urbanol, Urbanyl, Urbadan, Sympazan, Urbanil, Mystan, Noiafren, Castilium, Aedon, Clobam, Clobamax

Classification

Chemical: Benzodiazepine
Chemical: Medicine
Psychoactive: Depressant
Tag: Anticonvulsant
Tag: Anxiolytic
Tag: Habit-Forming

Effects

Ataxia
Sedation
Muscle Relaxation
Nausea
Anxiolytic
Sedative
Depersonalization
Derealization
Anxiety Suppression
Euphoria
Anxiety
Confusion
Appetite Suppression
Visual Acuity Suppression
Disinhibition
Dulled Perception
Open Eye Visuals
Double Vision

Routes of Administration

Oral

Dosage

Heavy: 60+ mg
Light: 5 – 10 mg
Common: 10 – 25 mg
Strong: 25 – 40 mg
Threshold: 5 mg

Duration

Onset: 0.33-0.67 h
After Effects: 12-48 h
Peak: 1-4 h
Offset: 6-12 h
Total Duration: 8-12 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu